Hematological Markers in Idiopathic Carpal Tunnel Syndrome
Evaluation of Inflammatory Hematological Markers in Idiopathic Carpal Tunnel Syndrome
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The carpal tunnel, located on the palmar side of the wrist, is bounded medially by the pisiform and hook of hamate, and laterally by the tuberosities of scaphoid and trapezium. The thick connective tissue (flexor retinaculum) covers these four bony prominences, forming a tunnel for the extrinsic flexor tendons of the fingers (flexor digitorum profundus, flexor digitorum superficialis, and flexor pollicis longus), keeping them in place during wrist flexion. The median nerve is the major peripheral nerve of the upper extremity. It originates from the lateral and medial cords of the brachial plexus. It progresses along the arm to the forearm, following a path through the carpal tunnel toward the wrist; here, it branches to provide motor support to the thenar muscle group and sensory innervation to the palmar surface. It innervates the thumb, index finger, middle finger, and half of the ring finger. Carpal Tunnel Syndrome (CTS) occurs when the tunnel narrows or the extrinsic flexor tendons or tendon sheaths swell. It is most commonly seen in the 3rd-5th decades and is three times more common in women than men. The narrowing in the carpal tunnel affects the median nerve, causing sensory disturbance symptoms in the innervated fingers. Symptoms can progress to thenar muscle weakness, leading to weakened grip strength.
Although the pathophysiology of CTS is multifactorial, it can be simplified as compression of the median nerve at the carpal tunnel level. The two most common compression sites are under the flexor retinaculum at the tunnel exit and the hook of hamate. Compression results from increased compartmental pressure in the carpal tunnel and decreased volume. The most common mechanism is hypertrophy of the synovial tissue surrounding the extrinsic flexor tendons of the hand. This hypertrophy may develop due to overuse, wrist trauma, or an underlying inflammatory process such as arthritis. Systemic diseases such as obesity, diabetes mellitus (DM), chronic kidney disease, rheumatoid arthritis, hypothyroidism, congestive heart failure, and pregnancy are also risk factors for CTS.
High body mass index (BMI) is a significant risk factor in developing CTS. A positive correlation between BMI and CTS severity has been reported. CTS is more common in patients with metabolic syndrome, which is characterized by abdominal obesity, atherogenic dyslipidemia, high blood pressure, insulin resistance or glucose intolerance, and is a prothrombotic and proinflammatory endocrinopathy. CTS severity is also higher in these patients.
Environmental workplace factors may promote the development of carpal tunnel syndrome. There is evidence that high levels of repetitive wrist movement increase the risk of carpal tunnel syndrome. There are dramatic changes in fluid pressure in the carpal tunnel according to wrist position; extension increases pressure 10-fold, and wrist flexion increases it 8-fold. Additionally, certain workplace psychosocial factors such as high psychological job demands, high job strain, low level of autonomy over one's work, and absence of interpersonal relationships providing social support are reported to be associated with carpal tunnel syndrome.
Despite various risk factors mentioned above, most CTS cases are still idiopathic cases where the cause cannot be determined. Therefore, comprehensive studies on pathophysiology and etiology continue. In CTS, which can lead to serious disability, a single factor often cannot explain the etiology. Therefore, many risk factors remain unidentified.
In idiopathic CTS, a pathophysiology that triggers each other in the form of ischemia, oxidative stress, low-grade chronic inflammation, and fibrosis, further narrowing the tunnel is emphasized.
In recent years, based on the knowledge that chronic inflammation creates an imbalance in peripheral blood neutrophil, lymphocyte, platelet, and monocyte counts, certain hematological indices have been developed by comparing these blood cells to each other. Commonly used ones are neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), systemic immune inflammation index (SII) calculated by platelet count X neutrophil count/lymphocyte count formula, and systemic immune response index (SIRI) calculated by neutrophil count X monocyte count/lymphocyte count formula. These indices are reported as simple and useful markers reflecting chronic inflammation in many diseases. In a study conducted with routine hemogram parameters in patients with idiopathic CTS, an increased neutrophil/lymphocyte ratio (NLR) was reported to correlate with CTS severity, and in another study, elevated CRP was reported to correlate with CTS severity, emphasizing systemic inflammation in the etiology of idiopathic CTS.
CTS is the most common cause of acroparesthesia. Beyond classical systemic diseases, growing evidence suggests that metabolic and inflammatory dysregulation may also influence disease severity. In a study comparing patients with moderate and severe CTS, no significant differences were found in terms of age, sex, occupational risk factors, or systemic comorbidities such as diabetes mellitus, hypothyroidism, rheumatoid arthritis, cardiovascular disease, and renal failure. However, higher body mass index (BMI) was significantly more frequent in the severe CTS group. In addition, biomarkers reflecting metabolic and inflammatory status, including the triglyceride-to-HDL (TG/HDL) ratio and composite indices such as the C-reactive protein-albumin-lymphocyte (CALLY) index, may provide further insight into disease severity by capturing underlying low-grade inflammation and metabolic imbalance. These parameters may therefore contribute to explaining inter-individual differences in CTS severity beyond traditional risk factors.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Altindag
-
Ankara, Altindag, Turkey (Türkiye), 06230
- Department of Physical Therapy and Rehabilitation, University of Health Sciences, Ankara Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age between 18-65 years
- Having undergone Electromyography (EMG) testing for Carpal Tunnel Syndrome (CTS)-like symptoms
- Recent complete blood count, C-Reactive Protein (CRP), and albumin available
Exclusion Criteria:
- Age below 18 or above 65 years
- Pregnancy
- History of wrist trauma or surgical operation
- Diabetes mellitus
- Chronic kidney disease
- Gout
- Rheumatoid arthritis
- Connective tissue disease
- Thyroid disorders
- Acromegaly
- Polyneuropathy
- Thoracic outlet syndrome
- Brachial plexopathy
- Cervical disc herniation
- Presence of cardiac pacemaker
- Steroid use
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Case-Idiopathic Carpal Tunnel Syndrome Patient Group
Patients diagnosed with idiopathic Carpal Tunnel Syndrome, confirmed by electrodiagnostic testing, with no identifiable secondary causes.
Evaluated for inflammatory hematological markers, TG/HDL, and CALLY index.
|
|
Control- Healthy Control Group (Electrodiagnostically Screened)
Age- and sex-matched asymptomatic individuals without Carpal Tunnel Syndrome, confirmed through electrodiagnostic testing.
Used as controls for comparison of inflammatory markers, TG/HDL, and CALLY index.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of Systemic Inflammation Response Index (SIRI) as an Inflammatory Marker
Time Frame: up to 4 weeks
|
The systemic inflammation response index (SIRI) is calculated as neutrophil count × monocyte count / lymphocyte count. It reflects the combined effect of neutrophil and monocyte-driven innate immunity versus lymphocyte-mediated adaptive immunity. SIRI has been proposed as a robust marker of inflammation in several chronic diseases. In the current study, SIRI was evaluated in individuals with and without Carpal Tunnel Syndrome (CTS) to investigate its potential as an indicator of inflammatory burden. |
up to 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of Electromyography severity
Time Frame: up to 4 weeks
|
EMG (Electromyography) intensity/amplitude is an important parameter used in the electrical measurement of muscle activity. Electromyography (EMG) severity;
|
up to 4 weeks
|
|
Evaluation of Platelet/Lymphocyte Ratio (PLR) as an Inflammatory Marker
Time Frame: up to 4 weeks
|
Platelet/lymphocyte ratio (PLR) is another hematological marker that reflects systemic inflammation. During inflammatory responses, platelet counts often increase while lymphocyte counts decrease, resulting in an elevated PLR. Platelets play an active role in inflammation by releasing inflammatory mediators and interacting with leukocytes. PLR, calculated from routine blood tests, has been increasingly used in the assessment of inflammatory conditions. In this study, PLR values were compared between patients with Carpal Tunnel Syndrome (CTS) and healthy controls to evaluate its association with inflammation in CTS. |
up to 4 weeks
|
|
Evaluation of Monocyte/Lymphocyte Ratio (MLR) as an Inflammatory Marker
Time Frame: up to 4 weeks
|
Monocyte/lymphocyte ratio (MLR) is a peripheral blood marker used to assess systemic inflammatory status. Monocytes contribute to chronic inflammation and tissue remodeling, while lymphocytes are typically reduced in inflammatory states. An increased MLR may reflect an enhanced inflammatory response. Like other ratios, MLR can be easily derived from complete blood count parameters. In this study, MLR was analyzed in patients with and without Carpal Tunnel Syndrome (CTS) to explore its relevance as a potential inflammatory biomarker. |
up to 4 weeks
|
|
Evaluation of Neutrophil/Lymphocyte Ratio (NLR) as an Inflammatory Marker
Time Frame: up to 4 weeks
|
In inflammatory diseases, the immune response often leads to an increase in circulating neutrophils and a decrease in lymphocytes, resulting in an elevated neutrophil/lymphocyte ratio (NLR). This parameter has recently gained attention as a simple, cost-effective, and readily available marker of systemic inflammation. NLR is derived from routine complete blood count tests and reflects the balance between innate (neutrophils) and adaptive (lymphocytes) immune responses. In the present study, NLR was compared between patients with Carpal Tunnel Syndrome (CTS) and healthy controls to investigate its potential role as a marker of inflammation in CTS. |
up to 4 weeks
|
|
Evaluation of Systemic Immune-inflammation Index (SII) as an Inflammatory Marker
Time Frame: up to 4 weeks
|
The systemic immune-inflammation index (SII) is a composite marker calculated using the formula: platelet count × neutrophil count / lymphocyte count. It simultaneously incorporates three types of immune cells and is considered a more comprehensive indicator of the systemic inflammatory status. Elevated SII levels have been associated with various inflammatory and immune-mediated conditions. In this study, SII values were compared between CTS patients and healthy controls to assess its potential utility in identifying inflammatory activity in CTS. |
up to 4 weeks
|
|
Comparison of vitamin TG/HDL
Time Frame: up to 4 weeks
|
Comparison of TG/HDL between case and control groups
|
up to 4 weeks
|
|
- Comparison of C-Reactive Protein levels (CRP) and CALLY
Time Frame: up to 4 weeks
|
- Comparison of C-Reactive Protein levels (CRP) levels between case and control groups.
CRP is an acute phase protein used as an inflammatory marker.
CRP's half-life is approximately 19 hours, making it a responsive marker that can indicate both the onset of inflammation and the response to treatment relatively quickly.
CALLY (C-reactive protein-Albumin-Lymphocyte) index is a composite scoring system that integrates CRP, albumin, and lymphocyte count to reflect both inflammatory status and nutritional-immune condition simultaneously.
|
up to 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nadide Koca, M.D., University of Health Sciences, Ankara Training and Research Hospital, TURKEY
Publications and helpful links
General Publications
- Newington L, Harris EC, Walker-Bone K. Carpal tunnel syndrome and work. Best Pract Res Clin Rheumatol. 2015 Jun;29(3):440-53. doi: 10.1016/j.berh.2015.04.026. Epub 2015 May 27.
- Werner RA, Andary M. Carpal tunnel syndrome: pathophysiology and clinical neurophysiology. Clin Neurophysiol. 2002 Sep;113(9):1373-81. doi: 10.1016/s1388-2457(02)00169-4.
- Otelea MR, Nartea R, Popescu FG, Covaleov A, Mitoiu BI, Nica AS. The Pathological Links between Adiposity and the Carpal Tunnel Syndrome. Curr Issues Mol Biol. 2022 Jun 8;44(6):2646-2663. doi: 10.3390/cimb44060181.
- Malakootian M, Soveizi M, Gholipour A, Oveisee M. Pathophysiology, Diagnosis, Treatment, and Genetics of Carpal Tunnel Syndrome: A Review. Cell Mol Neurobiol. 2023 Jul;43(5):1817-1831. doi: 10.1007/s10571-022-01297-2. Epub 2022 Oct 10.
- Tonga F, Bahadir S. The Factors Associated with Carpal Tunnel Syndrome Severity. Turk Neurosurg. 2022;32(3):392-397. doi: 10.5137/1019-5149.JTN.34519-21.2.
- Zvonickova K, Rhee A, Sandy-Hindmarch O, Furniss D, Wiberg A, Schmid AB. Systemic low-grade C-reactive protein is associated with proximal symptom spread in carpal tunnel syndrome. Pain Rep. 2024 Apr 10;9(3):e1156. doi: 10.1097/PR9.0000000000001156. eCollection 2024 Jun.
- Gunes M, Buyukgol H. Correlation of neutrophil/lymphocyte and platelet/lymphocyte ratios with the severity of idiopathic carpal tunnel syndrome. Muscle Nerve. 2020 Mar;61(3):369-374. doi: 10.1002/mus.26791. Epub 2020 Jan 9.
- Wang RH, Wen WX, Jiang ZP, Du ZP, Ma ZH, Lu AL, Li HP, Yuan F, Wu SB, Guo JW, Cai YF, Huang Y, Wang LX, Lu HJ. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front Immunol. 2023 Feb 13;14:1115031. doi: 10.3389/fimmu.2023.1115031. eCollection 2023.
- Padua L, Cuccagna C, Giovannini S, Coraci D, Pelosi L, Loreti C, Bernabei R, Hobson-Webb LD. Carpal tunnel syndrome: updated evidence and new questions. Lancet Neurol. 2023 Mar;22(3):255-267. doi: 10.1016/S1474-4422(22)00432-X. Epub 2022 Dec 13.
- Joshi A, Patel K, Mohamed A, Oak S, Zhang MH, Hsiung H, Zhang A, Patel UK. Carpal Tunnel Syndrome: Pathophysiology and Comprehensive Guidelines for Clinical Evaluation and Treatment. Cureus. 2022 Jul 20;14(7):e27053. doi: 10.7759/cureus.27053. eCollection 2022 Jul.
- Che X, Chen Q, He D, Fan L. Correlation of CRP/Albumin ratio and low serum albumin with the risk of major adverse cardiovascular events in elderly patients with chronic total occlusion. Hereditas. 2025 Dec 29;163(1):19. doi: 10.1186/s41065-025-00622-1.
- Razavi AS, Karimi N, Bashiri F. The relationship of serum lipid profiles and obesity with the severity of carpal tunnel syndrome. Pan Afr Med J. 2021 Jun 1;39:90. doi: 10.11604/pamj.2021.39.90.27234. eCollection 2021.
- Yano K, Kawabata A, Ikeda M, Suzuki K, Kaneshiro Y, Egi T. Hypercholesterolemia Is Associated with the Subjective Evaluation of Postoperative Outcomes in Patients with Idiopathic Carpal Tunnel Syndrome Who Undergo Surgery: A Multivariate Analysis. Plast Reconstr Surg. 2018 Apr;141(4):941-948. doi: 10.1097/PRS.0000000000004228.
- Zhu D, Lin YD, Yao YZ, Qi XJ, Qian K, Lin LZ. Negative association of C-reactive protein-albumin-lymphocyte index (CALLY index) with all-cause and cause-specific mortality in patients with cancer: results from NHANES 1999-2018. BMC Cancer. 2024 Dec 5;24(1):1499. doi: 10.1186/s12885-024-13261-y.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AnkaraTRH-FTR-NK-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carpal Tunnel Syndrome (CTS)
-
NCT07400562Completed
-
NCT07364604CompletedCarpal Tunnel Syndrome (CTS)
-
NCT07230782CompletedCarpal Tunnel Syndrome (CTS)
-
NCT07327723Not yet recruitingCarpal Tunnel Syndrome (CTS)
-
NCT07294157RecruitingCarpal Tunnel Syndrome (CTS)
-
NCT07283874Not yet recruiting
-
NCT07269613Not yet recruitingCarpal Tunnel Syndrome (CTS)
-
NCT07248124Recruiting
-
NCT07509437CompletedSimultaneous vs. Postponed Carpal Tunnel Release (CTR) During Distal Radius Fracture (DRF) Fixation.Carpal Tunnel Syndrome (CTS)
-
NCT07486284Enrolling by invitationCarpal Tunnel Syndrome (CTS)